CDA | Evidence Driven
CDA | Evidence Driven

Zydelig for Chronic Lymphocytic Leukemia – Details

Details

Files
Generic Name:
Idelalisib
Project Status:
Complete
Therapeutic Area:
Chronic lymphocytic leukemia
Manufacturer:
Gilead Sciences, Inc.
Brand Name:
Zydelig
Project Line:
Reimbursement Review
Project Number:
PC0057-000
Performance Metric:
Achieved
Strength:
100mg and 150mg tablets
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia
Funding Request:
In combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)
Review Status:
Complete
Sponsor:
Gilead Sciences, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Idelalisib (Zydelig) CLL - Final pERC Recommendation Final Recommendation August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Final Clinical Guidance Report Guidance Reports August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Final Economic Guidance Report Guidance Reports August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Initial Recommendation View PDF
Idelalisib (Zydelig) CLL - PAG Feedback on Initial Recommendation Feedback August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Manufacturer Feedback on Initial Recommendation Feedback August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Patient Advocacy Group (LC) Feedback on Initial Recommendation Feedback August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Patient Advocacy Group (LC) COI Declarations COI Declarations August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Patient Advocacy Group (CLLPAG & LLSC) Feedback on Initial Recommendation Feedback August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Patient Advocacy Group (CLLPAG) COI Declarations COI Declarations August 18, 2015 View PDF
Idelalisib (Zydelig) CLL - Patient Advocacy Group (LLSC) COI Declarations COI Declarations August 18, 2015 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : September 2, 2015